Resilience and Beyond the Acute Phase Challenges: Case Series on Prolonged COVID-19 Infection in Immunocompromised Individuals.

IF 2.9 3区 医学 Q2 INFECTIOUS DISEASES
Infection and Drug Resistance Pub Date : 2024-10-29 eCollection Date: 2024-01-01 DOI:10.2147/IDR.S479764
Kridsanai Gulapa, Dararat Eksombatchai, Tananchai Petnak, Viboon Boonsarngsuk
{"title":"Resilience and Beyond the Acute Phase Challenges: Case Series on Prolonged COVID-19 Infection in Immunocompromised Individuals.","authors":"Kridsanai Gulapa, Dararat Eksombatchai, Tananchai Petnak, Viboon Boonsarngsuk","doi":"10.2147/IDR.S479764","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>COVID-19 infection is associated with an increased risk of severe illness and adverse outcomes in individuals with immunocompromising conditions. Immunocompromised patients may have difficulty with viral clearance, which can lead to persistent infection and potential relapses in viral replication.</p><p><strong>Case presentation: </strong>Herein, we present four cases of persistent COVID-19 pneumonia in immunocompromised patients, including those with diffuse large B-cell lymphoma, polyarteritis nodosa, and end-stage renal disease post-kidney transplant. Three patients had previously received rituximab. Notably, all patients in this cohort demonstrated positive anti-receptor binding-domain immunoglobulin G (IgG) and negative anti-nucleocapsid IgG values.</p><p><strong>Conclusion: </strong>Persistent COVID-19 infection should be considered in the differential diagnosis of immunocompromised patients who exhibit ongoing symptoms or lack of improvement in chest X-ray findings following initial COVID-19 treatment. Early recognition, beyond the diagnosis of post-COVID organizing pneumonia, may significantly improve clinical outcomes with timely and appropriate treatment.</p>","PeriodicalId":13577,"journal":{"name":"Infection and Drug Resistance","volume":"17 ","pages":"4727-4732"},"PeriodicalIF":2.9000,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531297/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection and Drug Resistance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IDR.S479764","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: COVID-19 infection is associated with an increased risk of severe illness and adverse outcomes in individuals with immunocompromising conditions. Immunocompromised patients may have difficulty with viral clearance, which can lead to persistent infection and potential relapses in viral replication.

Case presentation: Herein, we present four cases of persistent COVID-19 pneumonia in immunocompromised patients, including those with diffuse large B-cell lymphoma, polyarteritis nodosa, and end-stage renal disease post-kidney transplant. Three patients had previously received rituximab. Notably, all patients in this cohort demonstrated positive anti-receptor binding-domain immunoglobulin G (IgG) and negative anti-nucleocapsid IgG values.

Conclusion: Persistent COVID-19 infection should be considered in the differential diagnosis of immunocompromised patients who exhibit ongoing symptoms or lack of improvement in chest X-ray findings following initial COVID-19 treatment. Early recognition, beyond the diagnosis of post-COVID organizing pneumonia, may significantly improve clinical outcomes with timely and appropriate treatment.

恢复能力和超越急性期的挑战:免疫力低下者长期感染 COVID-19 的病例系列。
背景:COVID-19 感染会增加免疫力低下者患重症和不良后果的风险。免疫力低下的患者可能难以清除病毒,从而导致持续感染和病毒复制的潜在复发:在此,我们介绍了四例免疫功能低下患者的持续性 COVID-19 肺炎,包括弥漫大 B 细胞淋巴瘤、结节性多动脉炎和肾移植后终末期肾病患者。三名患者曾接受过利妥昔单抗治疗。值得注意的是,该队列中所有患者的抗受体结合域免疫球蛋白 G (IgG) 值均为阳性,而抗核壳 IgG 值均为阴性:结论:COVID-19感染持续存在,免疫力低下的患者在最初接受COVID-19治疗后症状持续存在或胸部X光检查结果无改善,应在鉴别诊断中予以考虑。除了 COVID 后机化性肺炎的诊断外,早期识别可通过及时和适当的治疗显著改善临床预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Infection and Drug Resistance
Infection and Drug Resistance Medicine-Pharmacology (medical)
CiteScore
5.60
自引率
7.70%
发文量
826
审稿时长
16 weeks
期刊介绍: About Journal Editors Peer Reviewers Articles Article Publishing Charges Aims and Scope Call For Papers ISSN: 1178-6973 Editor-in-Chief: Professor Suresh Antony An international, peer-reviewed, open access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventative strategies to minimize the development and spread of resistance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信